Open Access Open Access  Restricted Access Subscription Access

An Objectives, Mechanism of Action, Administration, Adverse Effects, Drug-Drug Interactions, Contra Indications, Toxicity and Health Care Team Outcomes of Quinapril Drug

Moni Theresa. Tsappidi, Muralinath E., Srinivas G., Guruprasad M., Ramanjaneyulu D.V.

Abstract


In the 1980s, the angiotensin-converting enzyme inhibitor (ACEi) quinapril was developed.  One drug called Quinapril is used to control hypertension, which is a major risk factor for coronary heart disease. Quinapril is also used off-label to treat renal dysfunction in people with diabetes and chronic heart failure (CHF), slowing its progression.  Angiotensin-converting enzyme (ACE), a crucial component of the renin-angiotensin-aldosterone system (RAAS), is inhibited by quinapril, a non-sulfhydryl ACEi. Quinapril exhibits in an effective manner lowered systolic blood pressure by 13 mm Hg and diastolic blood pressure by 10 mm Hg in approximately 2 out of 3 individuals. As is true for most drugs in this class, the medication regimen may be enhanced or reduced based on patient response.

This activity explains about the indications, mechanism of action, administration, adverse events, contraindications, monitoring, and toxicity of quinapril. Additionally, as required by interprofessional teams for the management of patients with hypertension and other cardiovascular co-morbidities, this article addresses important quinapril-related points.

Full Text:

PDF

References


Frank, G. J., Knapp, L. E., & McLain, R. W. (1989). Overall tolerance and safety of quinapril in clinical trials. Angiology, 40(4 Pt 2), 405–415.

Sedman, A. J., & Posvar, E. (1989). Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure. Angiology, 40(4 Pt 2), 360–369.

Maclean, D. (1989). Quinapril: A double-blind, placebo-controlled trial in essential hypertension. Angiology, 40(4 Pt 2), 370–381.

Begg, E. J., Robson, R. A., Bailey, R. R., Lynn, K. L., Frank, G. J., & Olson, S. C. (1990). The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment. British Journal of Clinical Pharmacology, 30(2), 213–220.

Drugs for chronic heart failure. (2021). Medical Letter on Drugs and Therapeutics, 63(1626), 89–96.

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., ... Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), e263–e421.

Dominguez, L. J., Barbagallo, M., Kattah, W., Garcia, D., & Sowers, J. R. (1995). Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. American Journal of Hypertension, 8(8), 808–814.

Raia, J. J., Barone, J. A., Byerly, W. G., & Lacy, C. R. (1990). Angiotensin-converting enzyme inhibitors: A comparative review. DICP: The Annals of Pharmacotherapy, 24(5), 506–525.

Squire, I. B., Macfadyen, R. J., Lees, K. R., Hillis, W. S., & Reid, J. L. (1994). Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure. British Journal of Clinical Pharmacology, 38(2), 117–123.

Anderson, T. J., Elstein, E., Haber, H., & Charbonneau, F. (2000). Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). Journal of the American College of Cardiology, 35(1), 60–66.

Marinescu, M. A., Löffler, A. I., Ouellette, M., Smith, L., Kramer, C. M., & Bourque, J. M. (2015). Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC: Cardiovascular Imaging, 8(2), 210–220.

Kaplan, H. R., Taylor, D. G., Olson, S. C., & Andrews, L. K. (1989). Quinapril—a preclinical review of the pharmacology, pharmacokinetics, and toxicology. Angiology, 40(4 Pt 2), 335–350.

Kieback, A. G., Felix, S. B., & Reffelmann, T. (2009). Quinaprilat: A review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. Expert Opinion on Drug Metabolism & Toxicology, 5(10), 1337–1347.

Miller, M. A., Texter, M., Gmerek, A., Robbins, J., Shurzinske, L., & Canter, D. (1994). Quinapril hydrochloride effects on renal function in patients with renal dysfunction and hypertension: A drug-withdrawal study. Cardiovascular Drugs and Therapy, 8(2), 271–275.

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., ... Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: Executive summary. Journal of the American College of Cardiology, 79(17), 1757–1780.

Pucci, M., Sarween, N., Knox, E., Lipkin, G., & Martin, U. (2015). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: Risks versus benefits. Expert Review of Clinical Pharmacology, 8(2), 221–231.

American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. (2019). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. Obstetrics & Gynecology, 133(1), e26–e50.

National Institute of Child Health and Human Development. (2024, November 15). Quinapril. In Drugs and Lactation Database (LactMed®). https://www.ncbi.nlm.nih.gov/books/NBK501356/

National Institute of Diabetes and Digestive and Kidney Diseases. (2018, February 11). Quinapril. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https://www.ncbi.nlm.nih.gov/books/NBK548956/

Canter, D., Frank, G. J., Knapp, L. E., & McLain, R. W. (1990). The safety profile of quinapril: Is there a difference among ACE inhibitors? Clinical Cardiology, 13(6 Suppl 7), VII39–VII42.

Alderman, C. P. (1996). Adverse effects of the angiotensin-converting enzyme inhibitors. Annals of Pharmacotherapy, 30(1), 55–61.

Palmquist, S., & Mathews, B. (2017). Isolated intestinal type angioedema due to ACE-inhibitor therapy. Clinical Case Reports, 5(5), 707–710.

Bharate, S. S. (2021). Critical analysis of drug product recalls due to nitrosamine impurities. Journal of Medicinal Chemistry, 64(6), 2923–2936.

Hubers, S. A., & Brown, N. J. (2016). Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation, 133(11), 1115–1124.

Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Muñoz, D., Smith, S. C., Virani, S. S., Williams, K. A., Yeboah, J., & Ziaeian, B. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 74(10), e177–e232.


Refbacks

  • There are currently no refbacks.